MINT-C · M602011084

Multicenter, randomized, placebo-controlled Phase 3 study evaluating the safety and efficacy of Xeomin® injections for preventing chronic migraine, including an extended follow-up period.

A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of chronic migraine. EudraCT: 2024-515682-34

Sponsor: MERZ

Phase: III

Status: Follow-up

View clinical trials catalogue

Public study eligibility criteria

Inclusion

  • * Participant has a diagnosis of CM with or without aura according to the International Classification of Headache Disorders Edition 3 criteria for ≥ 12 months and is able to distinguish migraine headaches from all other types of headaches;
  • * Participant age \ 1 prescribed drug for the preventive treatment of migraine;
  • * Discontinuation of anti-calcitonin gene-related peptide (CGRP) / anti-CGRP receptor monoclonal antibody treatment less than 5 months prior to screening.